Skip to Content
Global News Select

Stryker Posts Higher 3Q Profit on Increasing Unit Volume

By Kimberly Chin

Stryker Corp. said profit rose in the third quarter as sales picked up due to an increase in unit volume although the company warned that the ongoing pandemic can still weigh on deferrable medical procedures.

The medical-technology company's profit was $621 million, or $1.63 a share, up from $461 million, or $1.23 a share, a year earlier. Adjusted profit was $2.14 a share. Analysts polled by FactSet were expecting adjusted earnings of $1.41 a share.

Net sales rose to $3.74 billion from $3.59 billion in the comparable period a year earlier, ahead of analysts' expectations of $3.41 billion.

The Kalamazoo, Mich., company's total operating expenses declined by 5.9% to $1.6 billion.

The measures to contain the spread of the Covid-19 pandemic has led to the postponement of many deferrable medical procedures, which will continue to have a negative effect on the company's financial results, Stryker said.

Write to Kimberly Chin at

(END) Dow Jones Newswires

October 29, 2020 16:41 ET (20:41 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.